The independent source for health policy research, polling, and news.
201 - 220 of 458 Results
Some doctors are getting licensed in multiple states so they can use telemedicine and mail-order pharmacies to provide medication abortions to more women. At the same time, states are cracking down on telemedicine abortions, blunting the efforts of out-of-state doctors.
A corporate CEOs call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
The Biden administrations request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate synthetic nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHNs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nations mental health crisis and what can be done about it.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimers drug that scientists say has not been proven to work.
Researchers in Montana have found that unsafe levels of copper can leach into the cocktail in less than half an hour.
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of PDUFA also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimers disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHNs Julie Rovner to discuss these issues and more.
Health and Human Services Secretary Xavier Becerra is drawing criticism for his hands-off handling of the covid crisis even though the heads of the Centers for Disease Control and Prevention, National Institutes of Health, and FDA report to him. Meanwhile, the Department of Labor looks to enforce mental health parity laws that have failed to achieve their goals. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNs Noam N. Levey, who reported and wrote the latest KHN-NPR Bill of the Month episode about a large emergency room bill for a small amount of medical care.
Medicare officials tentatively plan to restrict the use of a controversial Alzheimers drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more.
In this episode, host Dan Weissmann talks to reporters who investigated the shortage of tests and traced the U.S. rapid-testing problem back to government agencies.
There were variants, vaccine hesitancy and messaging mix-ups. And, despite campaign promises, Biden and his administration sometimes took actions or made statements without waiting for full scientific evidence to back them up.
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals loudly that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHNs Julie Rovner to discuss these issues and more.
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
Experts weigh in as the federal government urges everyone to get boosted amid concerns over omicron, a new covid variant.
Hospitals in Montana and Idaho reported threats and harassment from public officials and family members of patients who were denied treatment with a drug not authorized to treat covid-19.
President Joe Bidens social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner previews next weeks Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
You probably wont be testing everyone at your Thanksgiving table for covid because the tests are expensive and hard to find. Why? The federal government is partly to blame.
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimers disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the An Arm and a Leg podcast.
President Joe Biden unveiled a compromise Build Back Better framework shortly before taking off for key meetings in Europe, but its unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the partys health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHNs Julie Rovner to discuss these issues and more.
Negotiations on the health parts of President Joe Bidens domestic agenda are getting serious but have yet to produce a deal every Democrat can support. Meanwhile, the Food and Drug Administration remains without a nominated leader but manages to take the first steps toward approving over-the-counter hearing aids. Joanne Kenen of Politico and Johns Hopkins, Tami Luhby of CNN and Rachel Cohrs of Stat join KHNs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read too.
穢 2026 KFF